NKGen Biotech Inc
NASDAQ:NKGN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
NKGen Biotech Inc
EPS (Diluted)
NKGen Biotech Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
N
|
NKGen Biotech Inc
NASDAQ:NKGN
|
EPS (Diluted)
-$3
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
Baker Hughes Co
NASDAQ:BKR
|
EPS (Diluted)
$2
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Schlumberger NV
NYSE:SLB
|
EPS (Diluted)
$2
|
CAGR 3-Years
-1%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
4%
|
|
|
Halliburton Co
NYSE:HAL
|
EPS (Diluted)
$1
|
CAGR 3-Years
-5%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Symbotic Inc
NASDAQ:SYM
|
EPS (Diluted)
$0
|
CAGR 3-Years
-7%
|
CAGR 5-Years
43%
|
CAGR 10-Years
N/A
|
|
|
R
|
Reddit Inc
NYSE:RDDT
|
EPS (Diluted)
$2
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
NKGen Biotech Inc
Glance View
NKGen Biotech Inc is a US-based company operating in industry. The company is headquartered in Santa Ana, California. The company went IPO on 2021-05-21. NKGen Biotech, Inc. is a clinical-stage biotechnology company. The firm is focused on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies to treat neurodegenerative and oncological diseases utilizing its (SuperNK) SNK (super-activated) platform. SNK involves the infusion of one’s own activated NK cells into the body to improve immune system function, eliminate diseased or abnormal cells and prevent recurrence. SNK uses pure NK cells harvested from the patient’s blood, activated and infused back into the patient’s body. SNK has a therapeutic potential within the areas of cancer, autoimmune and neurodegenerative diseases. Autologous NK cell immunotherapy is a treatment that provides immune enhancement using pure NK cells harvested from a patient’s body. The company is also focused on conducting clinical trials with its super-activated NK cell therapy in patients with neurodegenerative disease (SNK01) and cancer (SNK02).
See Also
What is NKGen Biotech Inc's EPS (Diluted)?
EPS (Diluted)
-3.6
USD
Based on the financial report for Dec 31, 2023, NKGen Biotech Inc's EPS (Diluted) amounts to -3.6 USD.
